Plasma Renin Activity and Aldosterone Concentrations in Hypertensive Cats with and without Azotemia and in Response to Treatment with Amlodipine Besylate

BackgroundRole of renin-angiotensin aldosterone system (RAAS) in feline systemic hypertension is poorly understood. ObjectivesExamine plasma renin activity (PRA) and plasma aldosterone concentrations (PAC) in normotensive and hypertensive cats with variable renal function and in response to antihypertensive therapy. AnimalsOne hundred and ninety-six cats >9years from first opinion practice. MethodsPRA, PAC, and aldosterone-to-renin ratio (ARR) were evaluated in cats recruited prospectively and grouped according to systolic blood pressure (SBP) and renal function (nonazotemic normotensive [Non-Azo-NT], nonazotemic hypertensive [Non-Azo-HT], azotemic normotensive [Azo-NT], azotemic hypertensive [Azo-HT]). Changes in PRA and PAC were evaluated with antihypertensive therapy (amlodipine besylate). ResultsPlasma renin activity (ng/mL/h; P=.0013), PAC (pg/mL; P<.001), and ARR (P=0.0062) differed significantly among groups. PRA (ng/mL/h) was significantly lower in hypertensive (Non-Azo-HT; n=25, median 0.22 [25th percentile 0.09, 75th percentile 0.39], Azo-HT; n=44, 0.33 [0.15, 0.48]) compared with Non-Azo-NT cats (n=57, 0.52 [0.28, 1.02]). Azo-HT cats had significantly higher PAC (n=22, 149.8 [103.1, 228.7]) than normotensive cats (Non-Azo-NT; n=26, 45.4 [19.6, 65.0], Azo-NT; n=18, 84.1 [38.6, 137.8]). ARR was significantly higher in Azo-HT (n=20, 503.8 [298.8, 1511]) than Azo-NT cats (n=16, 97.8 [77.0, 496.4]). Significant increase in PRA was documented with antihypertensive therapy (pretreatment [n=20] 0.32 [0.15-0.46], posttreatment 0.54 [0.28, 1.51]), but PAC did not change. Conclusions and Clinical ImportanceHypertensive cats demonstrate significantly increased PAC with decreased PRA. PRA significantly increases with antihypertensive therapy. Additional work is required to determine the role of plasma aldosterone concentration in the pathogenesis of hypertension and whether this relates to autonomous production or activation of RAAS without demonstrable increase in PRA.